Ocular Graft-Versus Host Disease (GVHD)

Ocular GVHD is eye inflammation and surface damage that can happen after an allogeneic (donor) bone-marrow or stem-cell transplant. Donor immune cells see parts of the patient’s tissues as “foreign,” attack them, and the lacrimal glands (tear glands), conjunctiva (the eye’s lining), cornea (the clear front window), and eyelids can all be involved. The result is usually a severe, stubborn form of dry eye disease that can scar the surface and blur vision if not treated early. FrontiersPMC

Ocular graft-versus-host disease is eye inflammation and damage that can happen after an allogeneic stem-cell or bone-marrow transplant. The new donor immune cells attack parts of the eye that keep the surface moist and smooth—especially the lacrimal (tear) glands, meibomian (oil) glands, conjunctiva (the thin lining over the white of the eye and inner lids), and the cornea. When those tissues are attacked, the tear film breaks down. That causes dryness, burning, light sensitivity, gritty feeling, redness, blurry/variable vision, and sometimes erosions, filaments, ulcers, or scarring on the cornea. In severe, untreated cases, it can threaten vision. oGVHD can occur alone or with GVHD in other organs. The eye problem can be mild and fluctuating or severe and constant; it often needs layered treatment and close follow-up. EyeWikiAmerican Academy of Ophthalmology

Pathophysiology

After transplant, the donor immune system sometimes misidentifies the patient’s tissues as “foreign.” In the eye, immune cells release signals (cytokines) that inflame the lacrimal gland (reducing watery tears) and the meibomian glands (reducing the oily layer that prevents evaporation). The surface cells and goblet cells (which make the mucus layer that lets tears spread smoothly) are also lost. The result is an “unstable” tear film: it breaks up too fast, becomes too salty (hyper-osmolar), and irritates nerves—creating a vicious cycle of more inflammation, more friction with each blink, and more damage. That’s why oGVHD often behaves like a severe evaporative + aqueous-deficient dry eye with extra immune injury layered on top. PubMedtearfilm.orgPMC

In GVHD today, doctors classify “acute vs. chronic” by the pattern of organ involvement, not just by the number of days after transplant (the old 100-day rule is outdated). Ocular involvement is a classic part of chronic GVHD. PMC

How does it happen?

1. Donor T-cells and B-cells misfire. The transplant’s immune cells get activated against the patient’s tissues. This touches off inflammation in the tear glands and on the eye’s surface. Over time, that inflammation can scar the lacrimal glands so they make fewer tears. It can also reduce goblet cells (which make the eye’s mucin), so the tear film loses stability and the surface dries out. Frontiers

2. Oil glands in the eyelids (meibomian glands) are damaged. These glands supply the tear film’s oily layer. In oGVHD they can drop out or shrink, which speeds up tear evaporation. Infrared meibography studies show progressive gland loss in many patients. PubMed

3. The surface stays inflamed. Tear samples from oGVHD patients often contain high levels of inflammatory molecules (for example, neutrophil elastase and MMP-9), which correlates with worse surface damage. PubMed

Types

Think of “types” here as clinical patterns and severity groupings, not different diseases.

A) By timing and context

• Chronic oGVHD: the usual form; part of body-wide chronic GVHD.

• Isolated ocular involvement vs. with systemic GVHD: eyes alone are less common; most patients also have skin, mouth, or other organ features. (Doctors follow NIH chronic GVHD rules to classify the whole patient.) PMC

B) By what tissue is most affected

• Aqueous-deficient dry eye (tear gland predominant): low tear production from scarred lacrimal glands; hallmark is very low Schirmer values. PMC

• Evaporative dry eye (meibomian gland predominant): oil layer is thin/patchy; tears break up too fast; meibography shows gland loss. PubMed

• Mixed dry eye: both mechanisms together (very common).

• Cicatricial conjunctivitis: scarring of the inner eyelids and conjunctiva; can cause symblepharon (adhesions), shortened fornices, and lid malposition. EyeWiki

• Corneal disease: punctate keratopathy, filaments, erosions, and in severe cases ulceration or melt. PMC

C) By severity

• NIH Eye Score (0–3): a simple 0–3 scale used across GVHD research and care to track symptoms and functional impact (e.g., how often artificial tears are needed and whether daily activities are affected). It’s sensitive to change and widely used. PMCAmerican Academy of Ophthalmology

• International Chronic oGVHD (ICOGVHD) criteria (2013): combine OSDI symptom score + Schirmer (without anesthesia) + corneal fluorescein staining + conjunctival injection into a point system that classifies no/probable/definite oGVHD. Nature

---

Causes

These are things that make ocular GVHD more likely or more severe. Not every patient has all of them.

1. Having chronic GVHD elsewhere in the body. Eye disease is much more common when systemic chronic GVHD is present. PMC

2. Older donor or recipient age. Age is a consistent risk factor in chronic GVHD cohorts. EyeWiki

3. HLA mismatch between donor and recipient. The bigger the mismatch, the higher the GVHD risk overall. EyeWiki

4. History of acute GVHD. Prior acute GVHD episodes raise later chronic GVHD risk, including eye disease. EyeWiki

5. Female-to-male donation (sex-mismatch). This pairing is a known GVHD risk factor in general. (Part of the broader chronic GVHD literature.) PMC

6. Conditioning treatments (e.g., total-body irradiation, certain chemotherapies). These can injure the thymus and ocular surface, promoting immune dysregulation and dryness. EyeWiki

7. Peripheral blood stem-cell source vs. marrow. Some cohorts find more chronic GVHD with PBSCs. (Eye involvement often mirrors overall cGVHD.) PMC

8. Environmental “desiccating stress.” Hot, dry, windy air and low humidity increase symptoms and may independently raise oGVHD risk. AstCT Journal

9. Meibomian gland dropout. Loss of oil glands speeds evaporation and worsens irritation. PubMed

10. Goblet cell loss. With fewer mucin-producing cells, the tear film becomes unstable and the surface dries out. Frontiers

11. Persistent ocular surface inflammation. Elevated tear proteases (like neutrophil elastase and MMP-9) correlate with more severe damage. PubMed

12. Eyelid margin disease (blepharitis) and telangiectasia. These disrupt the lipid layer and irritate the surface. EyeWiki

13. Contact lens wear (especially if poorly fitted) post-transplant. Can irritate a vulnerable surface. (Clinical-practice caution echoed in reviews.) PMC

14. Infections on a dry, damaged surface. Ulcers or pseudomembranes worsen scarring and pain if not promptly treated. EyeWiki

15. Systemic medications that dry the eye (some antihistamines/anticholinergics, diuretics, etc.) add to symptoms. (General dry-eye principles applied in GVHD care.) tfosdewsreport.org

16. Steroid side effects. Long-term topical/systemic steroids (often needed for GVHD) can raise IOP (glaucoma) or cause cataracts, compounding vision problems. American Academy of Ophthalmology

17. Limbal stem-cell stress or deficiency. Chronic inflammation can injure the corneal stem-cell niche, reducing surface healing capacity. (Described in oGVHD reviews.) PMC

18. Low tear clearance. Stagnant tears keep inflammatory molecules on the surface longer. (Dry-eye mechanism recognized in TFOS guidance.) laboratoriosthea.com

19. Neuropathic component. Nerve changes (reduced corneal sensitivity or abnormal sensations) can amplify symptoms and blink problems. (Reported in oGVHD/meibomian literature.) PMC

20. Pediatric non-reporting. Children often don’t voice symptoms, so disease is recognized late and looks “worse” at discovery. Nature

---

Common symptoms

1. Dryness that doesn’t go away with regular drops.

2. Burning or stinging (a “sunburned eyes” feeling).

3. Gritty, sandy, or foreign-body sensation.

4. Redness (conjunctival hyperemia).

5. Stringy mucus or filaments stuck to the cornea.

6. Light sensitivity (photophobia).

7. Watery eyes (reflex tearing)—ironically common in very dry eyes.

8. Blurry or fluctuating vision, worse with reading or screens.

9. Pain with wind, air-conditioning, or low humidity.

10. Contact lens intolerance.

11. Eyelid margin soreness or crusting; visible telangiectasia on the lid edges.

12. Eye fatigue and frequent blinking during tasks.

13. Morning stickiness or lids stuck together.

14. Sensitivity to smoke or perfumes.

15. In severe cases, sharp pain, non-healing erosions, or sudden blur from ulcer/melt—these are emergencies. (These symptom clusters are well-described in oGVHD reviews and clinical guides.) PMC

---

Diagnostic tests

Doctors choose a mix of tests to confirm oGVHD, measure severity, and rule out look-alikes. There isn’t one perfect test. Most clinics combine symptoms, eye-surface tests, and a GVHD context.

A) Physical exam tests (what the eye doctor sees and measures at the slit lamp)

1. Visual acuity and refraction. Checks how clearly you see; oGVHD often causes fluctuating blur that improves briefly after blinking. EyeWiki

2. External eyelid exam. Looks for lid margin thickening, crusting, and tiny dilated vessels (telangiectasia), which signal oil-gland disease. EyeWiki

3. Meibomian gland expressibility and oil quality. Gentle pressure on the lid edge shows whether the oil comes out easily and looks clear or toothpaste-thick. (Core part of oGVHD assessments.) EyeWiki

4. Tear meniscus height. The small “reservoir” of tears at the lower lid; a thin meniscus hints at low tear volume. (Standard dry-eye exam element.) laboratoriosthea.com

5. Corneal fluorescein staining. A blue light shows surface punctate spots; the pattern and density track disease activity. Nature

6. Conjunctival lissamine-green (or rose bengal) staining. Highlights damaged, unprotected cells and mucin loss on the white of the eye. laboratoriosthea.com

7. Filament check. Thin mucus “threads” stuck to the cornea can cause sharp pain; seeing them confirms a severe surface problem. PMC

8. Symblepharon/fornix exam. Doctor looks for adhesions and shortened fornices—signs of cicatricial conjunctivitis. EyeWiki

9. Blink quality (rate and completeness). Incomplete blinks leave the cornea exposed and worsen evaporation. (Dry-eye best practice.) laboratoriosthea.com

10. Corneal sensitivity (cotton-wisp). Very reduced sensation hints at nerve involvement and poor healing. EyeWiki

B) Manual/bedside tests (quick measurements done in clinic)

11. Schirmer test (without anesthesia). A paper strip measures basic tear production over 5 minutes; very low values support oGVHD. Nature

12. Schirmer (with anesthesia). Removes the irritation reflex and isolates baseline secretion from the lacrimal gland. (Helpful when values are borderline.) laboratoriosthea.com

13. Fluorescein TBUT (tear breakup time). A dye + blue light show how fast tears “break up” after a blink; short TBUT means an unstable film (often from meibomian issues). laboratoriosthea.com

14. Meibum quality grading. Clinician grades the color/consistency of oil; thicker or toothpaste-like oil points to blocked glands. EyeWiki

15. Dye disappearance / tear-clearance test. Tracks how quickly dye washes out—slow clearance means inflammatory mediators sit longer on the eye. laboratoriosthea.com

C) Laboratory & pathological tests (objective markers and tissue assessment)

16. Tear osmolarity. A tiny sample gauges saltiness; higher values signal an unstable tear film and dry-eye stress. (Used alongside other tests.) EyeWikilaboratoriosthea.com

17. Point-of-care MMP-9 (InflammaDry). A quick swab shows if surface inflammation is high; often positive in oGVHD flares. PMC

18. Tear cytokine panels (research/advanced). Studies show raised IL-6, IL-8, and other mediators; can serve as biomarkers in trials. PMC

19. Impression cytology. A gentle filter paper lifts surface cells to count goblet cells and look for squamous metaplasia—a hallmark of chronic irritation and oGVHD. EyeWiki

20. Conjunctival biopsy (select cases). Rarely needed; confirms scarring patterns or rules out infection/other causes when the picture is unclear. EyeWiki

D) Electrodiagnostic tests (rarely needed; used to rule out other problems)

• Visual evoked potentials (VEP) or electroretinography (ERG) are not routine for oGVHD, because the problem is usually on the ocular surface, not the retina/optic nerve. They might be used if vision is weirdly reduced and the exam suggests a posterior-segment issue unrelated to surface disease. (Posterior involvement in GVHD is uncommon and often due to treatment side effects rather than GVHD itself.) EyeWiki

E) Imaging tests (to document and track changes)

• Infrared meibography. Shows meibomian gland dropout over time; oGVHD often causes rapid gland loss. PubMed

• Anterior-segment OCT. Non-contact imaging of the tear meniscus height and corneal layers; helpful to track tear volume and healing. (Dry-eye methodology.) laboratoriosthea.com

• In vivo confocal microscopy. Microscopic, in-clinic imaging of corneal nerves, inflammatory cells, and meibomian glands; useful in clinics with access, and in research. EyeWiki

• Non-invasive TBUT (video-topography). Measures tear stability without dye by watching reflection patterns on the cornea. laboratoriosthea.com

• Corneal topography/tomography. Maps surface shape and regularity; irregular astigmatism suggests surface disease or scarring. (Dry-eye workup standard.) laboratoriosthea.com

• Slit-lamp photography. Baseline and follow-up photos to monitor staining, filaments, and scarring over time. (Routine documentation.) PMC

Non-pharmacological treatments

Each item explains what it is, purpose, and how it works.

1. Education + early referral
   Purpose: Catch oGVHD early and layer care. How: Baseline and frequent eye checks after transplant so treatment starts before damage snowballs. EyeWiki

2. Preservative-free artificial tears (daytime)
   Purpose: Replace missing moisture. How: Add water and lubricants to dilute saltiness and lower friction. Use single-dose, preservative-free vials to avoid surface toxicity. PubMed

3. Lubricating gels/ointments (bedtime)
   Purpose: Night protection. How: Thick lubricants coat the cornea to reduce overnight drying and morning pain. PubMed

4. Moisture-chamber glasses / wraparound eyewear
   Purpose: Cut evaporation. How: Traps humidity around the eyes to keep tears from vanishing into dry air. PubMed

5. Humidifier + environment control
   Purpose: Raise room humidity, reduce drafts/airflow to eyes. How: Less evaporation, fewer symptoms. PubMed

6. Blink training + screen breaks
   Purpose: Stabilize tear film. How: 20-20-20 rule; full blinking spreads oil and water evenly. PubMed

7. Warm compresses
   Purpose: Melt thick oils in meibomian glands. How: Heat softens meibum, making it flow and rebuilding the oily tear layer that slows evaporation. PubMed

8. Lid hygiene
   Purpose: Reduce lid margin inflammation/biofilm. How: Gentle lid scrubs or hypochlorous acid wipes limit bacteria and toxins that irritate the surface. PubMed

9. Meibomian gland expression (in-office)
   Purpose: Open blocked oil glands. How: Controlled pressure/thermal devices express stagnant oil and improve the lipid layer. PubMed

10. Thermal pulsation (e.g., LipiFlow)
    Purpose: Device-based heat + pressure for MGD. How: Liquefies and evacuates thickened oils to improve evaporation control. PubMed

11. Intense Pulsed Light (IPL) for MGD
    Purpose: Calm lid inflammation and telangiectasia. How: Light pulses reduce abnormal lid blood vessels and inflammation, improving meibum quality (selected cases). ScienceDirect

12. Punctal plugs (temporary silicone)
    Purpose: Keep tears on the eye longer. How: Tiny plugs block tear drainage, raising tear time on surface; often combined with other steps. (Permanent cautery is surgical; see surgeries below.) EyeWiki

13. Scleral lenses / PROSE devices
    Purpose: “Liquid bandage.” How: A large lens vaults over the cornea and holds a reservoir of sterile fluid all day, shielding nerves and promoting healing; excellent for severe oGVHD dryness and pain. ScienceDirect

14. Bandage soft contact lens (short-term)
    Purpose: Comfort and epithelial protection during erosions. How: Reduces friction while the surface heals (with infection precautions). PubMed

15. Self-retained amniotic membrane (office placement) for acute surface crisis
    Purpose: Jump-start healing. How: Biological membrane delivers anti-inflammatory and pro-healing factors for non-healing epithelial defects or severe filaments. (More invasive AMT is under “surgeries.”) PMCAjo

16. Topical mucolytic support via clinician-directed compounded drops
    Purpose: Reduce sticky filaments. How: Short courses (see drug section for N-acetylcysteine details) can dissolve mucus strands that tug on the cornea. EyeWiki

17. Allergen avoidance & eye protection outdoors
    Purpose: Lower extra triggers. How: Sunglasses/wraps reduce wind/UV; avoiding smoke/irritants lowers flare risk. PubMed

18. Preservative minimization
    Purpose: Prevent toxicity on an already fragile surface. How: Prefer preservative-free tears and limit benzalkonium chloride exposure. PubMed

19. Coordinated care with the transplant/GVHD team
    Purpose: Align systemic and ocular control. How: Adjust systemic immunosuppression when eye disease signals broader GVHD activity. AstCT Journal

20. Frequent follow-up with stepwise escalation
    Purpose: Prevent complications. How: The plan is layered: lubrication → evaporation control → drainage control → inflammation control → devices → surgical rescue if needed. EyeWiki

---

Drug treatments

1. Topical corticosteroid (e.g., prednisolone acetate 1% or loteprednol)
   Dose/time: Short courses, often QID then taper per response.
   Purpose: Rapidly calm surface inflammation in flares.
   Mechanism: Broad anti-inflammatory effect on cytokines/leukocytes.
   Key cautions: Can raise eye pressure, promote cataract, increase infection risk—use the lowest effective dose and monitor. EyeWiki

2. Topical cyclosporine A (0.05%–0.1%)
   Dose/time: Typically BID (some refractory cases use higher frequency); onset may take weeks.
   Purpose: Long-term steroid-sparing control of surface inflammation and tear production support.
   Mechanism: Calcineurin inhibitor that reduces T-cell–driven inflammation; increases goblet cells in dry eye.
   Side effects: Burning/tingling on instillation, rare infection. Lippincott JournalsPMC

3. Topical tacrolimus (0.03–0.05% drops/ointment; off-label)
   Dose/time: Often BID (ointment at night for comfort) in oGVHD refractory to steroids or cyclosporine.
   Purpose: Steroid-sparing anti-inflammatory when cyclosporine is not enough or not tolerated.
   Mechanism: Calcineurin inhibition; potent T-cell suppression on the ocular surface.
   Side effects: Stinging/burning; monitor for infection when used long term. RCTs show benefit in chronic oGVHD. PMCAAO JournalLippincott Journals

4. Lifitegrast 5% ophthalmic solution
   Dose/time: BID.
   Purpose: Reduce dry-eye inflammation; sometimes used in oGVHD as adjunct.
   Mechanism: LFA-1/ICAM-1 blockade to reduce T-cell adhesion and cytokine signaling.
   Side effects: Dysgeusia (bad taste), burning, irritation. (Evidence specific to oGVHD is limited but it is commonly tried for inflammatory dry eye.) PubMed

5. Autologous serum eye drops (ASED)
   Dose/time: Commonly QID to hourly depending on severity (strengths vary, 20–100%).
   Purpose: Bio-replacement tears for severe surface disease; support epithelial healing.
   Mechanism: Patient’s own serum brings growth factors, vitamin A, albumin that mimic natural tears.
   Side effects: Requires blood draw, cold-chain handling; generally well tolerated. Strong oGVHD data. PubMedLippincott Journals

6. Platelet-rich plasma (PRP) eye drops
   Dose/time: Typically QID to six times daily; protocols vary.
   Purpose: Another biologic tear for stubborn disease; may help nerve and surface recovery.
   Mechanism: Delivers concentrated platelet growth factors (PDGF, EGF, TGF-β) that promote healing.
   Side effects: Preparation logistics; generally safe. PMC+1

7. N-acetylcysteine (NAC) 5–10% compounded eye drops
   Dose/time: Often QID for weeks in filamentary keratitis.
   Purpose: Break down sticky mucus filaments that tug on the cornea in severe oGVHD dry eye.
   Mechanism: Mucolytic; also inhibits matrix metalloproteinases that damage the epithelium.
   Side effects: Temporary burning; compounding required. PubMedScienceDirect

8. Topical azithromycin 1% (or short oral pulse)
   Dose/time: Drops BID for 2–4 weeks; oral pulse regimens vary.
   Purpose: Reduce lid margin inflammation and improve meibum in MGD-heavy oGVHD.
   Mechanism: Macrolide anti-inflammatory effect, alters meibomian secretions and bacterial load.
   Side effects: Irritation with drops; GI upset if oral. PubMed

9. Oral doxycycline (50–100 mg/day)
   Dose/time: Weeks to months.
   Purpose: Anti-inflammatory for MGD and corneal surface (reduces MMP-9).
   Mechanism: Sub-antibiotic metalloproteinase inhibition and rosacea/MGD control.
   Side effects: Sun sensitivity, reflux; avoid in pregnancy/children. Nature

10. Secretagogues (pilocarpine 5 mg QID or cevimeline 30 mg TID; off-label for tears)
    Purpose: Stimulate exocrine secretion; may help some with dryness (more robust for dry mouth; variable for dry eye).
    Mechanism: Muscarinic agonists increase gland output.
    Side effects: Sweating, flushing, GI upset; caution with asthma/heart disease. Evidence for dry eye is mixed; use selectively. Medscape ReferenceBioMed Central

Important: Steroids are for short-term flares; the backbone of long-term control is steroid-sparing anti-inflammatories (cyclosporine/tacrolimus/lifitegrast) plus tear/evaporation/plug strategies. Severe cases benefit from biologic tears (ASED/PRP) and scleral lenses. EyeWiki

---

Dietary & supportive supplements

Evidence varies; always clear with your transplant and eye teams—drug interactions are real.

1. Omega-3 fatty acids (fish oil; e.g., 1000–3000 mg/day EPA+DHA)
   Function: May change meibum quality and lower surface inflammation.
   Mechanism: Anti-inflammatory lipid mediators.
   Note: In general dry eye, the large DREAM RCT showed no superiority over placebo; results in oGVHD are mixed—use as adjunct only. PMC

2. Hydration (water intake target individualized)
   Function: Keeps tears less concentrated; supports mucins.
   Mechanism: Systemic hydration lowers tear osmolarity burden. PubMed

3. Dietary vitamin A (within RDA)
   Function: Supports ocular surface epithelial health.
   Mechanism: Epithelial differentiation and mucin support. (Topical vitamin A ointment may be used clinically for keratinization.) PubMed

4. Flaxseed oil (ALA) (1–2 g/day)
   Function: Alternative omega-3 source; weaker ocular evidence than fish oil.
   Mechanism: Converts (inefficiently) to EPA/DHA; anti-inflammatory potential. PubMed

5. Hyaluronic acid (oral, doses vary 120–240 mg/day in studies)
   Function: May improve skin/ocular surface hydration in some reports; most evidence is for topical HA drops.
   Mechanism: Hydrophilic polymer retains water. PubMed

6. Vitamin D (replete if deficient; dose per labs)
   Function: Immune modulation; deficiency correlates with worse dry eye in some studies.
   Mechanism: Immunoregulatory effects on T cells and epithelia. PubMed

7. Antioxidant-rich diet (berries, leafy greens, colorful veg)
   Function: General anti-inflammatory milieu.
   Mechanism: Polyphenols/antioxidants may dampen oxidative stress on the ocular surface. PubMed

8. Avoid high-omega-6 processed oils
   Function: Reduce pro-inflammatory eicosanoid load.
   Mechanism: Balance dietary fatty acids toward less inflammatory signaling. PubMed

9. Limit alcohol (dehydrating)
   Function: Reduces dryness spikes.
   Mechanism: Alcohol increases diuresis and dehydrates mucosa. PubMed

10. Caffeine moderation
    Function: Prevent diuresis-related dryness.
    Mechanism: Mild diuretic effect; individualized tolerance. PubMed

11. Probiotics (adjunct only)
    Function: Gut–immune axis support (weak ocular-specific evidence).
    Mechanism: Modulates systemic inflammation; evidence in dry eye is not definitive. PubMed

12. Zinc (within RDA)
    Function: Epithelial healing cofactor.
    Mechanism: Enzyme function in repair pathways; avoid excess. PubMed

13. L-carnitine (doses vary 1–2 g/day in some ocular surface studies)
    Function: Osmoprotectant/anti-inflammatory potential.
    Mechanism: Cellular osmoprotection; limited clinical data. PubMed

14. Curcumin (standardized extract with pepper/optimized forms)
    Function: General anti-inflammatory supplement; limited ocular data; watch drug interactions.
    Mechanism: NF-κB pathway modulation. PubMed

15. Collagen peptides (10 g/day; adjunct)
    Function: General tissue support; evidence for eyes is minimal—use only as supportive nutrition.
    Mechanism: Amino-acid supply for connective tissue. PubMed

Bottom line: nutrition can support but does not replace medical therapy. For omega-3s, set realistic expectations given DREAM trial results. PMC

---

Regenerative / stem-cell–related” therapies

1. Ruxolitinib (JAK1/2 inhibitor; systemic)
   Dose: 10 mg orally BID for cGVHD (per FDA label; adjust for cytopenias and interactions).
   Function: For steroid-refractory chronic GVHD; eye may improve when overall GVHD improves.
   Mechanism: Blocks JAK-STAT signaling that drives GVHD inflammation.
   Key effects/risks: Cytopenias, infections; needs hematology oversight. U.S. Food and Drug AdministrationFDA Access Data

2. Belumosudil (ROCK2 inhibitor; systemic)
   Dose: 200 mg orally once daily (adjust with strong CYP3A inducers or PPI).
   Function: For chronic GVHD after ≥2 prior lines; helps fibrosis/inflammation.
   Mechanism: ROCK2 pathway modulation reduces profibrotic and inflammatory signaling.
   Risks: GI upset, infections, lab abnormalities; specialist monitoring. FDA Access DataPMC

3. Ibrutinib (BTK inhibitor; systemic)
   Dose: 420 mg orally once daily for cGVHD after failure of ≥1 systemic therapy (adult; pediatric dosing differs).
   Function: Another option for steroid-refractory chronic GVHD; ocular signs can improve with systemic control.
   Mechanism: Inhibits B-cell receptor signaling (BTK).
   Risks: Bleeding risk, atrial fibrillation, infections; careful drug-interaction review. U.S. Food and Drug AdministrationRxAbbVie

4. Axatilimab (anti-CSF-1R monoclonal antibody; systemic)
   Dose: Per FDA approval for cGVHD after ≥2 lines; vial sizes approved 2025; dosing individualized by weight/label.
   Function: Targets pro-fibrotic macrophages; an option when others fail.
   Mechanism: CSF-1R blockade reduces macrophage-driven inflammation/fibrosis.
   Risks: Liver enzyme elevations, musculoskeletal pain, infections—hematology guidance needed. U.S. Food and Drug AdministrationTargeted Oncology

5. Autologous Serum Eye Drops (ASED; biologic topical)
   Dose: Often 20–100%, QID to hourly, long-term.
   Function: Regenerative “tear” with growth factors; improves symptoms, staining, and sometimes vision in oGVHD.
   Mechanism: Delivers vitamin A, EGF, albumin and other tear-like components.
   Risks: Logistics; generally safe. PubMed

6. Platelet-Rich Plasma (PRP) Eye Drops (biologic topical)
   Dose: Typically QID–6x/day; protocols vary.
   Function: High growth-factor content to promote epithelial and nerve health when standard care fails.
   Mechanism: Platelet-derived cytokines (PDGF, TGF-β, EGF).
   Risks: Preparation/handling; supportive evidence growing. PMC

(Emerging/experimental: human amniotic epithelial stem-cell approaches and other cellular/regenerative strategies are under study; these are not routine care yet.) Haematologica

---

Surgeries (what is done & why)

1. Punctal occlusion by thermal cautery (permanent) or surgical closure
   Why: For severe aqueous deficiency where temporary plugs help but fall out. Permanently blocks tear drainage to keep tears (and drops) on the eye longer. EyeWiki

2. Amniotic membrane transplantation (AMT; sutured or self-retained)
   Why: To heal persistent epithelial defects, reduce inflammation, and protect the cornea during severe oGVHD flares. Often buys time while other therapies work. Benefits can be temporary and some severe cases need repeat AMT. aes.amegroups.orgPubMed

3. Tarsorrhaphy (partial lid closure)
   Why: Reduces exposure and evaporation in critical cases, lowering risk of infection, ulceration, or perforation while the surface stabilizes. EyeWiki

4. Symblepharon release with mucous-membrane graft (for scarring/fornix shortening)
   Why: Restores lid-globe mobility and space for tears/lenses when conjunctival scarring glues tissues together. EyeWiki

5. Corneal transplantation (DALK or PK) for scarring/perforation
   Why: When corneal structure is lost or vision is severely damaged despite maximal therapy. Requires meticulous surface optimization pre- and post-op. EyeWiki

---

Prevention strategies (practical)

1. Baseline eye exam before/soon after transplant to set a plan and catch early signs. EyeWiki

2. Early, regular lubricants (preservative-free tears/gels) at the first hint of dryness. PubMed

3. Humidity + wraparound protection at home/work to cut evaporation. PubMed

4. Avoid preservatives when possible; use unit-dose tears. PubMed

5. Lid hygiene + warm compress routine to preserve meibomian function. PubMed

6. Screen time habits (blink breaks) to reduce exposure-related flares. PubMed

7. Coordinate with transplant team so systemic GVHD control supports the eyes. AstCT Journal

8. Sun/wind protection outdoors (glasses, hats). PubMed

9. Stop smoking and avoid smoke/irritants. PubMed

10. Report changes early (new pain, light sensitivity, discharge) to prevent ulcers. ScienceDirect

---

When to see a doctor urgently

• Sudden increase in pain, light sensitivity, or vision blur, especially with a non-healing defect or a new white spot on the cornea—possible ulcer or perforation risk.

• Filament-related sharp pain, erosions not improving, or a stringy discharge that sticks to the cornea.

• Steroid side effects: halos, headache, or rising eye pressure symptoms.

• Any rapid change after a new systemic GVHD medicine—coordinate with hematology and ophthalmology. ScienceDirect

---

What to eat and what to avoid

Do eat: a balanced, anti-inflammatory pattern—fish (if permitted), leafy greens, colorful vegetables, nuts/seeds, whole grains, adequate water. These choices support overall healing and may improve meibum quality. PubMed
Consider (adjunct only): omega-3s if you and your team agree; set expectations (the large DREAM trial didn’t show clear benefit vs placebo in general dry eye). PMC
Avoid/limit: ultra-processed, high-omega-6 fried foods; excess alcohol (dehydrating); smoking. PubMed

---

Frequently asked questions

1) Is oGVHD the same as “just dry eye”?
No. It behaves like severe dry eye plus immune attack on tear-making tissues. That’s why it can be tougher to control and needs layered therapy. EyeWiki

2) Can ocular symptoms appear even if the rest of my GVHD seems quiet?
Yes. oGVHD can flare independently, though it often tracks with overall GVHD. Close coordination with the transplant team helps. AstCT Journal

3) Will this go away?
Some improve over time; others need ongoing care. The goal is comfort, vision, and protection of the cornea using a stepwise plan. EyeWiki

4) Are steroid drops safe?
Short bursts can be very helpful, but long-term unsupervised use risks pressure rise and cataract. Always taper under supervision. EyeWiki

5) How long until cyclosporine/tacrolimus help?
Weeks, sometimes months. They are steroid-sparing and work best used consistently along with lubrication/evaporation control. Lippincott Journals

6) Are scleral lenses worth trying?
For many with moderate-to-severe oGVHD, yes. They create a liquid bandage and can dramatically reduce pain while improving vision. ScienceDirect

7) Do punctal plugs help?
Often, yes—especially when tear volume is low. Permanent cautery is an option if plugs keep falling out. EyeWiki

8) What if filaments keep forming?
Compounded N-acetylcysteine drops and amniotic membrane can help in stubborn cases, along with aggressive lubrication and MGD care. PubMedPMC

9) Can blood-derived drops (ASED/PRP) help?
Yes, evidence supports ASED and growing data support PRP for severe disease, often with symptom and staining improvement. PubMedPMC

10) Will systemic GVHD drugs help my eyes?
Controlling systemic inflammation with agents like ruxolitinib, belumosudil, ibrutinib, axatilimab can indirectly help eyes in appropriate patients. These are hematology-managed. U.S. Food and Drug AdministrationFDA Access Data

11) Can I use any over-the-counter tear?
Choose preservative-free single-use vials. Avoid benzalkonium chloride when possible. Thicker gels at night can help. PubMed

12) Are omega-3 supplements a must?
No. Some people like them, but high-quality evidence (DREAM trial) didn’t show clear benefit for typical dry eye; use only as an adjunct. PMC

13) What about lifitegrast?
It’s approved for dry eye and sometimes used in oGVHD as an anti-inflammatory adjunct; evidence specifically in oGVHD is limited. PubMed

14) When does surgery enter the picture?
When conservative measures fail or complications threaten vision—cautery, AMT, tarsorrhaphy, mucous-membrane grafts, corneal transplant are chosen based on the problem. EyeWiki

15) What’s the single most important habit?
Layered care done every day: preservative-free lubrication, evaporation control, lid care—and keep close follow-up so your plan is adjusted quickly. EyeWiki

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 12, 2025.